- Home
- GMAB vs OVV Comparison
GMAB vs OVV Comparison
Compare GMAB & OVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- OVV
- Stock Information
- Founded
- GMAB 1999
- OVV 2020
- Country
- GMAB Denmark
- OVV United States
- Employees
- GMAB N/A
- OVV N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- OVV Oil & Gas Production
- Sector
- GMAB Health Care
- OVV Energy
- Exchange
- GMAB Nasdaq
- OVV Nasdaq
- Market Cap
- GMAB 12.1B
- OVV 11.9B
- IPO Year
- GMAB N/A
- OVV N/A
- Fundamental
- Price
- GMAB $22.34
- OVV $43.32
- Analyst Decision
- GMAB Buy
- OVV Buy
- Analyst Count
- GMAB 9
- OVV 17
- Target Price
- GMAB $40.71
- OVV $56.31
- AVG Volume (30 Days)
- GMAB 1.9M
- OVV 2.3M
- Earning Date
- GMAB 02-12-2025
- OVV 02-26-2025
- Dividend Yield
- GMAB N/A
- OVV 2.77%
- EPS Growth
- GMAB 83.82
- OVV N/A
- EPS
- GMAB 16.85
- OVV 7.54
- Revenue
- GMAB $2,988,286,182.00
- OVV $9,562,000,000.00
- Revenue This Year
- GMAB $18.78
- OVV N/A
- Revenue Next Year
- GMAB $14.98
- OVV N/A
- P/E Ratio
- GMAB $13.00
- OVV $5.74
- Revenue Growth
- GMAB 30.67
- OVV N/A
- 52 Week Low
- GMAB $18.64
- OVV $36.91
- 52 Week High
- GMAB $31.88
- OVV $55.95
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- OVV 48.28
- Support Level
- GMAB $18.74
- OVV $43.50
- Resistance Level
- GMAB $22.55
- OVV $45.89
- Average True Range (ATR)
- GMAB 0.46
- OVV 1.45
- MACD
- GMAB 0.39
- OVV 0.02
- Stochastic Oscillator
- GMAB 94.64
- OVV 47.21
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.